Hoping to bag the latest Medibank dividend? Read this

Find out all you need to know about the private health insurer's upcoming dividend.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Medibank shares go ex-dividend tomorrow
  • This means they will no longer trade with a dividend attached
  • The dividend of 7.3 cents per share is the highest on record for the company

Time is running out to secure the Medibank Private Ltd (ASX: MPL) dividend.

Because by this time tomorrow, it will have reached its ex-dividend date, which is the time when shares trade without their dividend.

Here are some important details to keep in mind.

A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.

Image source: Getty Images

Medibank dividend

Medibank offers investors an interim dividend of 7.3 cents per share. It's fully franked too, so it carries certain tax benefits.

The dividend is payable on 29 September and has a trailing dividend yield of 3.7%.

You must hold Medibank shares before the ex-dividend date to receive the dividend.

Zooming out a little, we see that 7.3 cents per share is the highest dividend the company has ever offered investors in its dividend history, stretching back to 2015.

As my Fool colleague Cathryn pointed out, this is likely due to the company seeing a 9% boost in its net profit after tax (NPAT) for FY22 and, thus, being able to distribute higher profits to investors.

Medibank share price snapshot

Shares of Medibank currently trade for $3.655 each, up 0.69% on yesterday's closing price of $3.63.

The Medibank share price is up 9.25% year to date. Meanwhile, the S&P/ASX 200 Index (ASX: XJO) is down around 8% over the same period.

The company's current market capitalisation is approximately $10 billion.

Motley Fool contributor Matthew Farley has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Orthocell caps 26% surge this week with first US Military Surgery

The company's commercial rollout is off to a good start.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

This ASX health tech stock just hit a new record high. Could it go even higher?

Morgans believes there's still upside to be had.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Down almost 20% this year, how high could Mesoblast shares go?

The forward pipeline is looking promising.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Down 38% this year, is it finally time to buy low on CSL, ResMed and Pro Medicus shares?

These three stocks might be too cheap to ignore.

Read more »

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Healthcare Shares

How much would $10,000 become if CSL shares returned to their record high?

After a sharp decline, CSL is in a new phase. The question is what happens next.

Read more »

A man clenches his fists with glee having seen the share price go up on the computer screen in front of him.
Healthcare Shares

Why this ASX biotech stock just rocketed 89% today

Immutep shares rocket after a fresh FDA win

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Orthocell shares soar 22% on landmark US breakthrough

The company has been given approval to sell Remplir in more than 220 hospitals in the US.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX biotech stock just jumped again as its lead drug trial moves ahead

The latest trial milestone sends this ASX biotech stock higher today.

Read more »